Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a pharmaceutical company based in China, has announced that it has obtained marketing approval for its drug Yueruiling (leritrelvir) in Macau. The drug, a 3CL protease (3CLpro) inhibitor, is now authorized for use in treating mild to moderate cases of COVID-19.
Leritrelvir functions by targeting the main protease of the SARS-CoV-2 virus, inhibiting the cleavage of the virus’s precursor proteins, and subsequently preventing virus replication, which contributes to its therapeutic efficacy. This development follows the conditional approval for marketing of leritrelvir in China in March 2023, where it was also successfully included in the National Reimbursement Drug List (NRDL) through negotiations.- Flcube.com
